{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"}],"units":"Participants"}],"description":"Number of subjects who had treatment (AFM13) related Adverse Events.","groups":[{"description":"Subjects with Relapsed or Refractory CD30 positive Peripheral T-cell Lymphoma (PTCL).","id":"OG000","title":"Cohort A"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The safety set consisted of all subjects who received at least one dose of AFM13 and had at least one post-baseline safety assessment.","reportingStatus":"POSTED","timeFrame":"From the date of first treatment until the date of the last treatment + 37 days, up to 199 weeks.","title":"Number of Subjects With Treatment Related Adverse Event","type":"SECONDARY","unitOfMeasure":"Participants"}